Croatian(HR)English (United Kingdom)
Cilj radionice je upoznati istraživače čiji se rad temelji na in vitro i in vivo eksperimentalnim pristupima, s komplementarnim in silico metodama molekulskog modeliranja (MM), i njihovom primjenom u istraživanju, posebice raka. Na radionici će biti predstavljene neke od metoda MM koje se često koriste u interdisciplinarnom istraživačkom radu, kao što su komparativno modeliranje proteina, molekulsko uklapanje, molekulska dinamika, virtualni probir aktivnih kemijskih spojeva, modeliranje kvantitativnog odnosa strukture i aktivnosti (engl. Quantitative Structure-Activity Relationship, QSAR) te utjecaja fizikalno-kemijskih svojstava na ADME /Tox - obilježja kemijskih spojeva (engl. Absorption, Distribution, Metabolism and Excretion/Toxicology). Uz kratki opis temeljnih pretpostavka i teorijske pozadine, bit će dani konkretni primjeri iz prakse. U sklopu ove radionice polaznici će i praktično sudjelovati u pretraživanju javno dostupnih baza podataka kemijskih spojeva i njihovih bioloških interakcija. Također će biti upoznati s programima za vizualizaciju kemijskih spojeva i njihovih kompleksa (ChemAxon, VMD, Pymol).
Radionicu vode dr. sc. Višnja Stepanić, mag. chem. Marko Tomin i prof. dr. sc. Sanja Tomić s Instituta Ruđer Bošković (IRB) koji u svom radu primjenjuju metode MM u istraživanju interakcije kemijskih spojeva s biološkim molekulama, proteinima i nukleinskim kiselinama, u cilju razumijevanja mehanizma njihovog djelovanja i dizajna novih lijekova.
lung health 2018 banner

eacrCroatian Association for Cancer Research (CACR) is the association which brings together scientific and professional employees who are engaged in scientific and professional work in medicine, biology, biochemistry and related scientific fields related to cancer. The Society operates as a branch of the European Association for Cancer Research (EACR). EACR acts for 46 years and it is the most powerful European non-profit professional organization that covers both clinical and basic aspects of cancer research. Today there are over 10,000 members from about 90 countries worldwide. Membership of EACR forms individual members and national societies. There are over 170 members from Croatia registered to EACR, and Croatia is the only follower of the countries of the former state that has managed to keep representatives in the EACR Council. Council Committee is one of the main bodies of the Society, made by 25 members of the EACR who represent a particular country or their society. All EACR members from Croatia also become members of the Croatian Association for Cancer Research. Equally, all new members of the Croatian Association for Cancer Research automatically become members of the EACR.

The main objectives of the Croatian Association for Cancer Research are: 

a)  encouraging scientific and professional work in medicine, biology, biochemistry and related fields of science related to cancer research

b)  linking clinical and basic aspects of cancer research 

c)  promoting and enhancing communication among various groups by encouraging multidisciplinary program

d) encouraging initiatives for research programs of special importance to the area of cancer.

These guidelines are consistent with the mission of EACR, which aims to promote basic research with clearer directions to the prevention and treatment and care of cancer patients and whose members are active scientist, students, Emeriti, notables in areas related in any way with cancer, different aspects of cancer research, applications research and management.

CACR gives us a greater possibility of cooperation with related national organizations for cancer research in other countries in Europe and the world (BACR, ASEICA, MOT, AACR, etc.). In addition, we wish to strengthen connections between members of EACR in Croatia, but primarily to link researchers and as the Society to gain recognition in the field of cancer research as well as to enhance accessibility of the Society for young researchers.



Basic cancer research: why is it essential for the success of personalised cancer therapy?


The last decade has witnessed significant progress in cancer understanding and therapy: we can now identify the genetic drivers of individual tumours, and tailor drugs able to specifically intercept the driver mutations. While all agree that personalised cancer medicine is a clear outcome of the resources dedicated to cancer research over the last 50 years, some critics question the necessity for continuous investments in sub-fields other than clinical research and drug development. Herein, scientists from the European Association for Cancer Research (EACR) argue that the new ways to diagnose and treat cancer present important and hitherto unaddressed challenges for fundamental research of cancer. Allocating the resources needed for basic studies will likely fuel the next wave of achievements in the long way to conquer cancer.

Yosef Yarden and Carlos Caldes,

on behalf of the European Association for Cancer Research


Click here to read the 2-page position paper (reprinted in the 2014 EACR Yearbook)